Catalyst Pharmaceutical CPRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Agamree | $131.76M+96.9% | $117.09M+154% | $102.86M— | $85.53M— | $66.91M— | |
| Firdapse | $373.51M+15.7% | $358.38M+17.1% | $343.28M+17.0% | $330.4M+17.9% | $322.92M+20.6% | |
| Fycompa | $91.49M-35.8% | $113.34M-17.4% | $131.98M-4.6% | $140.25M-1.7% | $142.45M+1.2% | |
| Product Revenue Net | $596.75M+12.1% | $588.81M+20.3% | $578.11M+26.6% | $556.17M+28.5% | $532.29M+29.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Catalyst Pharmaceutical break its business down?
- Catalyst Pharmaceutical (CPRX) reports revenue by product across 4 parts — Agamree, Firdapse, Fycompa and Product Revenue Net. Each is extracted from the segment footnotes and tracked over time.
- Where does Catalyst Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Catalyst Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
